Can Biotech ETFs Continue Their Impressive Run In 2018? (IBB)

pills-drugs-biotech3
From Zacks: So far, it's been a good year for biotech stocks with the Nasdaq Biotechnology Index soaring 19.6% year to date.
NASDAQ:IBB November 14, 2017 7:09am

These ETFs Are Crushing The S&P 500 This Year (XBI)

stock-market-arrow-up
From Contrarian Outlook: If you're like most folks, you probably think it's tough for any fund to beat the S&P 500, especially in a year when the index jumped some 15%.
NYSE:XBI October 31, 2017 7:40am

Outflows Start To Hit The iShares NASDAQ Biotech ETF (IBB)

pills-drugs-biotech2
Analyst/ETF Trader Paul Weisbruch of Street One Financial brings us his daily fund flows update, which today examines a relatively muted ETF landscape that's seen smallish outflows in biotech and some renewed interest in volatility products ahead of earnings season.
NASDAQ:IBB October 24, 2017 11:46am

Traders Are Making Bullish Bets On Health Care ETFs (XLV)

healthcare
Healthcare stocks are moving higher today and there is accompanying call buying in November options that are listed on the largest name in the sector in terms of asset size, XLV (SPDR Health Care Select, Expense Ratio 0.14%, $17.5 billion in AUM).
NYSE:XLV October 17, 2017 12:55pm

Biotech Was The Hottest ETF Sector In The Third Quarter (IBB)

pills-drugs-biotech1
From Zacks: The broader market was pretty eventful in the third quarter. While geopolitical and political concerns were rife, those threats couldn't weigh on the equity market returns.
NASDAQ:IBB October 3, 2017 10:09am

Triple Leveraged Biotech Fund Sees Massive Outflows As Biotech Cools (LABU)

pills-drugs-biotech1
With Biotech stocks running into a speed-bump in the past couple sessions including today, we have seen some liquidations in the levered long LABU (Direxion Daily S&P Biotech Bull 3X, Expense Ratio 1.09%).
NYSE:LABU September 6, 2017 12:20pm

Positive Biotech Sentiment Takes Hold (IBB)

pills-drugs-biotech1
From Buzz Indexes: A common question we field relates to the transmission mechanism of sentiment to the share price: "How long does it take / when will it be reflected?"
NASDAQ:IBB July 6, 2017 2:58pm

It Might Be Time To Buy Pharmaceuticals (PJP)

white-pills
From Invesco: The pharmaceutical industry has lagged in recent years, due in part to political uncertainty, which has kept a lid on company share prices.
NYSE:PJP

Examining Niche Plays In The Biotech ETF Space (PBE)

pills-drugs-biotech4
We spoke about Biotech stocks on Monday and the torrid performance in the sector since mid-June, and the largest sector ETF in the space IBB (iShares Nasdaq Biotechnology, Expense Ratio 0.47%) continues to pack in assets in the near term.
NYSE:PBE June 29, 2017 2:10pm

More Gains Ahead For The Biotech ETF (IBB)?

pills-drugs-biotech3
From Dana Lyons: Last fall, we laid out the foundation for the current rally in pharmaceutical and biotech stocks; we take stock of those setups and the sectors’ present prospects.
NASDAQ:IBB

iShares NASDAQ Biotechnology Index ETF (IBB) Suddenly Looks Bullish

biotech-white-pills
It has been some time since we last spoke about the Biotech Equity segment in this piece, as the sector was simply not a solid performer through much of 2016 and has only recently come to life here in mid-2017.
NASDAQ:IBB June 26, 2017 11:50am

Analyst: Buy Biotech (IBB) On The Next Pullback

biotech-medical-pills
From David Dutkewych: Three weeks ago, I wrote about money pouring into U.S. stocks, specifically technology stocks. Now, just three weeks later, the high-flying tech sector is writing a different story.
NASDAQ:IBB June 23, 2017 6:51am

Examining The SPDR S&P Biotech ETF (XBI) Bullish Breakout

biotech-white-pills
From Chris Kimble: Biotech used to be an upside leader over the broad market coming off the 2009 lows. Biotech then officially gave up its leadership back in 2015, where it peaked and started underperforming the broad market.
NYSE:XBI June 22, 2017 6:37am

What’s Next For Biotech Stocks? (IBB)

biotech-white-pills
From Franklin Templeton Investments: Changing political policies and priorities can impact certain market sectors—for better or worse. Health care costs and prescription drug pricing were hot-button issues in the United States during the 2016 presidential election, and the Trump administration has been pushing forward its own health care agenda.
NASDAQ:IBB June 7, 2017 5:57am

Get Free Updates

Join over 50,000 investors who get the latest news from ETFDailyNews.com!

Most Popular


From Our Partners


Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories